PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.
暂无分享,去创建一个
R. Messmann | N. Gabrail | R. Naumann | J. Symanowski | M. Teneriello | S. Ghamande | G. Sutton | L. Gilbert | C. Lovejoy | G. Sutton